Metformin xr 500mg
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Metformin XR 500mg: Efficacy, Safety, and Pharmacokinetics
Bioequivalence and Safety of Metformin XR 500mg
Bioequivalence Studies
Metformin XR 500mg tablets have been extensively studied to ensure their bioequivalence to the immediate-release (IR) formulations. A study comparing generic metformin hydrochloride sustained-release (MH-SR) tablets (Boke®) with the innovator product Glucophage®-XR demonstrated that the two formulations are bioequivalent. The 90% confidence intervals (CIs) for key pharmacokinetic parameters such as the area under the curve (AUC) and maximum concentration (Cmax) were within the acceptable range of 80.00–125.00%. This indicates that the generic version can be used interchangeably with the branded product.
Safety Profile
The safety profile of metformin XR 500mg is comparable to that of the IR formulation. In the bioequivalence study, no severe adverse events were observed, although some adverse drug reactions (ADRs) were reported, including gastrointestinal issues and metabolic conditions. The incidence of ADRs was similar between the generic and innovator products, confirming the safety of the generic formulation.
Pharmacokinetics of Metformin XR
Steady-State Pharmacokinetics
The pharmacokinetic properties of metformin XR have been evaluated in multiple studies. One study assessed the steady-state pharmacokinetics of metformin XR using the GelShield Diffusion System technology. The results showed that metformin XR has a slower absorption rate compared to the IR formulation, with a time to maximum plasma concentration (Tmax) of 7 hours versus 3 hours for the IR formulation. Despite the slower absorption, the extent of absorption (AUC) was equivalent for both formulations, indicating that metformin XR provides a consistent therapeutic effect with once-daily dosing.
Comparative Efficacy
In a randomized clinical trial comparing metformin XR with metformin IR, the XR formulation showed a greater improvement in glycemic control, fasting plasma insulin (FPI), and homeostasis model assessment insulin resistance (HOMA-IR). Additionally, metformin XR was associated with a reduction in total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol levels, as well as lower levels of inflammatory markers such as TNF-α and hs-CRP. These findings suggest that metformin XR may offer superior metabolic benefits compared to the IR formulation.
Patient Satisfaction and Tolerability
Patient Preferences
Patients generally prefer the extended-release formulation due to its once-daily dosing regimen, which improves compliance and convenience. A study involving patients with type 2 diabetes mellitus who were switched from standard metformin to metformin XR reported high levels of patient satisfaction. The majority of patients experienced fewer gastrointestinal side effects and preferred the XR formulation over the IR version.
Long-Term Efficacy and Safety
In a long-term, double-blind trial, metformin XR demonstrated similar efficacy and safety to metformin IR over a 24-week period. Both formulations resulted in comparable reductions in HbA1c, fasting plasma glucose (FPG), and mean daily glucose (MDG) levels. The adverse event profiles were also similar, reinforcing the safety of metformin XR for long-term use.
Conclusion
Metformin XR 500mg is a bioequivalent and safe alternative to the immediate-release formulation, offering the added benefits of once-daily dosing and improved patient compliance. Its pharmacokinetic properties ensure consistent therapeutic effects, and it may provide superior glycemic control and metabolic benefits. Overall, metformin XR is a valuable option for the management of type 2 diabetes mellitus.
Sources and full results
Most relevant research papers on this topic